Ruhi Ahmed, Ph.D., RAC
Vice President of Regulatory and Government Affairs
Ruhi Ahmed joined Inozyme Pharma in April 2017 and serves as Vice President of Regulatory and Government Affairs. She has over 14 years of experience in the pharmaceutical and biotechnology industry in global regulatory drug development and program and portfolio management of assets from the preclinical to the commercial stage.
Prior to joining Inozyme Pharma, Dr. Ahmed held positions at Flag Therapeutics Inc., Ultragenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc., and Actavis Inc. (formerly Watson Pharmaceutical Inc.), where she led the preclinical, clinical and manufacturing strategy and submissions for multiple INDs and Marketing Applications for a variety of neuromuscular, respiratory, oncology and metabolic rare diseases. She also led the alliance management and program strategy for several investigational prodrugs, biologics and small molecules. Dr. Ahmed serves as a board member of the Parenteral Drug Association’s (PDA) Regulatory Affairs and Quality Advisory Board and is the U.S. lead of PDA’s Regulatory Affairs Interest Group.
She has co-authored the PDA Technical Report on “Quality Risk Management of Biotechnology Manufactured APIs,” as well as other technical reports and book chapters related to risk management and biopharmaceutical manufacturing. Dr. Ahmed earned her B.A. in biology and M.A. in biochemistry from the University of Texas at Austin and her M.Sc. in regulatory sciences and Ph.D. in molecular pharmacology and toxicology from the University of Southern California.